Enzalutamide tied to better outcomes than bicalutamide in mHSPC
09 Apr 2021
bởiAudrey Abella
A regimen comprising enzalutamide and androgen deprivation therapy (ADT) led to better outcomes compared with a bicalutamide-ADT regimen in an earlier setting of metastatic hormone-sensitive prostate cancer (mHSPC), particularly in Black men, a phase II study suggests.
